Eli Lilly shares bought on Trump’s behalf as his policies benefited drug firm

Key points

• Hundreds of thousands of dollars were invested in Eli Lilly on Donald Trump’s behalf earlier this year, according to financial disclosures, as the US drugmaker benefited from his administration’s move to expand access to blockbuster obesity treatments.
• Ethics filings revealed several thousand trades on the US president’s behalf tied to stocks and bonds in the first quarter of 2026, with a cumulative ​value of between $220m and about $750m.
• The forms, released last week, included securities linked to some of the largest companies in the US, including Apple, Boeing, Goldman Sachs, Meta Platforms, Microsoft and Nvidia.
• Trump has built strong ties with corporate America since his return to office in January 2025, and just last week took a string of CEOs – including those of Apple, Boeing, Goldman Sachs and Nvidia – with him on a state visit to China.
• The Trump Organization has denied the president “plays any role”...